Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coiled-coil domain-containing protein 134 (CCDC134)
- Target
- CCDC134
- Molecular classification
- Cytokine-like secreted protein, Molecular chaperone/adaptor protein, Nuclear protein (chromatin modification)
01
Overview
Coiled-coil domain-containing protein 134 (CCDC134) is a secreted and intracellular protein characterized by a coiled-coil domain. It functions as a cytokine-like molecule that enhances CD8+ T cell-mediated immunity and exhibits antitumor and anti-inflammatory effects. CCDC134 also operates as an ER-resident chaperone, ensuring proper maturation and trafficking of TLR4 by regulating gp96 glycosylation, and may participate in chromatin modification through interaction with the p300-CBP-associated factor complex. Deficiency of CCDC134 is embryonic lethal in mice, underscoring its essential role in development and tissue homeostasis. Its expression is implicated as a prognostic biomarker in breast cancer and genetic variants are associated with osteogenesis imperfecta. No direct pharmacological agents are currently reported to target CCDC134, but it remains a potential immune and cancer therapeutic target due to its role in T cell and receptor signal modulation.
- Other names
- CCDC134FLJ22349OI22coiled-coil domain-containing protein 134
02
Mechanism of action
Drugs targeting upstream/downstream of CCDC134 would likely act via: - Modulation of cytokine pathways - Inhibition/activation of immune cell signaling (TCR, TLR4 pathways) - Indirectly modulating antitumor immunity via T cell activity
03
Biological functions
Immune response modulator (stimulates CD8+ T cell activation, modulates Th1/Th17 responses)Positive regulation of signal transduction (e.g., TCR signaling, TLR4 maturation)Regulation of protein glycosylation and folding (chaperoning gp96 for TLR4 maturation)Chromatin/histone modification (affects p300/CBP associated factor complex)Embryonic development, angiogenesis, and cell proliferation
04
Disease associations
Cancer (prognostic biomarker in breast cancer)Osteogenesis imperfectaInflammation (modulates T cell-mediated inflammatory responses)Immunodeficiency (impacts T cell signaling, downstream immune defects)
05
Safety considerations
Embryonic lethality with complete CCDC134 loss (critical developmental function)Potential for immune dysregulation or increased infection risk if CCDC134 is displaced or inhibited
06
Biomarkers
CCDC134 expression in tumors (e.g., breast cancer prognosis)T cell activation/function markers linked to CCDC134 levels
Beyond the preview
Go deeper on Coiled-coil domain-containing protein 134 (CCDC134).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coiled-coil domain-containing protein 134 (CCDC134).